BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,253,000 | +36.7% | 199,236 | -10.9% | 0.01% | +25.0% |
Q2 2023 | $3,844,000 | +11.2% | 223,613 | +7.2% | 0.01% | 0.0% |
Q1 2023 | $3,457,000 | +117.7% | 208,613 | +0.1% | 0.01% | +100.0% |
Q4 2022 | $1,588,000 | -23.3% | 208,385 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $2,071,000 | +9.5% | 208,385 | 0.0% | 0.01% | +20.0% |
Q2 2022 | $1,891,000 | -10.6% | 208,385 | +0.1% | 0.01% | 0.0% |
Q1 2022 | $2,115,000 | -42.1% | 208,270 | -4.9% | 0.01% | -37.5% |
Q4 2021 | $3,652,000 | -63.2% | 218,922 | +3.4% | 0.01% | -70.4% |
Q3 2021 | $9,920,000 | -26.6% | 211,638 | -4.6% | 0.03% | -30.8% |
Q2 2021 | $13,520,000 | -1.0% | 221,768 | +0.0% | 0.04% | -9.3% |
Q1 2021 | $13,661,000 | -12.8% | 221,765 | +0.6% | 0.04% | -33.8% |
Q4 2020 | $15,672,000 | +89.6% | 220,408 | +0.0% | 0.06% | +62.5% |
Q3 2020 | $8,267,000 | +15.1% | 220,308 | 0.0% | 0.04% | +2.6% |
Q2 2020 | $7,184,000 | +12.4% | 220,308 | 0.0% | 0.04% | -4.9% |
Q1 2020 | $6,390,000 | – | 220,308 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |